HM-100760 / Hanmi - LARVOL DELTA

HM100760, a potent and selective MAT2A inhibitor, demonstrates a synergistic anticancer effect when combined with a PRMT5 inhibitor in MTAP-deleted cancer (AACR 2025) - "It exhibits potent antitumor activity as a monotherapy and demonstrates enhanced efficacy when combined with a PRMT5 inhibitor. Ongoing preclinical studies aim to further characterize HM100760's therapeutic potential and broaden its application in MTAP-deficient cancer treatment."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • MAT2A • MTAP

Hanmi Pharmaceutical Presents the Most Research Outcomes at AACR, Innovating Beyond Obesity to Cancer Treatment (Korea IT Times) - "Hanmi Pharmaceutical has announced that it will present the highest number of research outcomes among domestic pharmaceutical and bio companies at the prestigious American Association for Cancer Research (AACR) for three consecutive years, demonstrating the future value of its cancer drug pipeline."

Preclinical • Oncology

Hanmi Pharmaceuticals Unveils Next-Generation ’MAT2A Inhibitor’ Targeting Cancer Cell Metabolic Vulnerability [Google translation] (Hanmi Press Release) - "...Hanmi Pharmaceutical confirmed antitumor activity in various MTAP-deficient cell lines including pancreatic cancer and lung cancer through HM100760, and also demonstrated excellent anticancer effects in animal models with MTAP gene deletion. Based on these research results, Hanmi Pharmaceutical plans to enter nonclinical toxicity testing in the first half of next year."

New molecule • Preclinical • Lung Cancer • Pancreatic Cancer